Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience

[1]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  M. Roethke,et al.  PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  S. Fürst,et al.  Evaluation of Feasibility and Image Quality of 68Ga-DOTATOC Positron Emission Tomography/Magnetic Resonance in Comparison With Positron Emission Tomography/Computed Tomography in Patients With Neuroendocrine Tumors , 2013, Investigative radiology.

[4]  Felix Nensa,et al.  Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.

[5]  U. Haberkorn,et al.  PSMA as a target for radiolabelled small molecules , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Schwaiger,et al.  Sensitivity of PET/MRI to detect recurrence of prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Eveliina Arponen,et al.  Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. , 2012, European journal of radiology.

[9]  C. Claussen,et al.  Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. , 2012, Radiology.

[10]  U. Haberkorn,et al.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer , 2012, EJNMMI Research.

[11]  J. Osborne,et al.  Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy , 2012, Advances in urology.

[12]  W. Eckelman,et al.  [131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa) , 2012 .

[13]  R. Shah,et al.  Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[14]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[15]  U. Haberkorn,et al.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[17]  W. Eckelman,et al.  123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy , 2011, The Journal of Nuclear Medicine.

[18]  O. Ratib,et al.  18F-Fluorocholine integrated PET/MRI for the initial staging of prostate cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[20]  Philip S Low,et al.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.

[21]  H. Zaidi,et al.  Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence , 2008, Nuklearmedizin.

[22]  O. Ratib,et al.  Genf 2009 , 2009, Nuklearmedizin.

[23]  A. Pupi,et al.  Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer , 2008, La radiologia medica.

[24]  H. Zaidi,et al.  18F‐choline and/or 11C‐acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate‐specific antigen values (<1 ng/mL) after radical prostatectomy , 2007, BJU international.

[25]  V. Canzonieri,et al.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  A. Dirisamer,et al.  Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml? , 2005, Molecular Imaging and Biology.

[27]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.